Dabur Q4 Review: Analysts Expect Rural Demand, New Launches To Aid Growth
Analysts expect innovation, rising share in foods and beverages, costs cuts, expanding rural distribution, and new launches to aid Dabur India Ltd.'s overall growth.
The optimism stems from the ayurveda products maker reporting an 8% year-on-year increase in consolidated revenue in the quarter ended March even as higher raw material costs and subdued consumption weighed on its bottom line and margin.
The full fiscal witnessed a steep inflation of about 12.5%, eroding its margin like most other consumer goods makers. Dabur, however, gained market share across 99% of its product portfolio.
The company's management in a post-earnings analyst call said an early summer season, good harvest, and predictions of a normal monsoon are expected to result in a good demand in FY23.
But it also warned that inflationary pressures and a resultant consumption slowdown is likely to persist in the near-term even as it sees rural demand recovery to begin from the second half of FY23. Dabur aims to maintain FY23 operating margin at current levels with tight cost control.
Some of the strategies the company said it has adopted to drive growth are:
Accelerated pace of e-commerce innovations as it expects e-commerce to account for 20% of sales in the next four years from 6% of sales in FY22.
Intense direct distribution expansion.
Aggressive advertising spends.
Push more low-unit packs amid rampant downtrading.
Shares of Dabur fell as much as 2.96% but pared some of the losses to trade 1.85% lower as of 9:40 a.m. on Friday.
Of the 45 analysts tracking the company, 31 maintain a ‘buy', 12 suggest a ‘hold' and two recommend a ‘sell', according to Bloomberg data. The average of the 12-month consensus price target compiled by Bloomberg implies a 20.3% upside.
Here's what analysts have to say about Dabur's Q4 FY22 performance.
Motilal Oswal
Maintains ‘buy' at a target price of Rs 630 apiece.
The medium-term narratives on revenue growth are highly attractive, led by the initiatives taken by the new CEO in recent years on power brands, new launches, distribution expansion, and better analytics. As the impact of investing in these initiatives abates, Dabur's margin would expand in FY24.
In the near term, Dabur's sales visibility is better than its peers. Higher pricing power versus peers also augurs well for Dabur's earnings.
Reduces FY23 EPS forecast by 4% but maintains FY24 EPS estimate.
The inability to increase the pace of growth in its core Healthcare business has been the biggest disappointment.
Prabhudas Lilladher
Retains ‘accumulate' with a target price of Rs 603 apiece.
Near-term growth pressures expected given input cost inflation, slowdown in rural demand and overall decline in discretionary consumption.
Long-term outlook positive given innovation-led growth strategy; increasing share in foods and beverages category; low-unit packs allowing the company to leverage its distribution; cost-saving initiatives; strong rural distribution coverage of 90,000 villages; aggressive e-commerce expansion with incremental sales of 4-5% every year.
Dabur remains a formidable play on recovery in rural demand in the coming quarter.
Edelweiss Securities
Maintains ‘buy' but cuts target price to Rs 685 from Rs 720 earlier.
To capitalise on changing consumer preferences, Dabur is launching ayurveda-based products in oral care, hair care, health supplements, etc., which are likely to spur overall growth.
The company is expected to benefit from growth recovery in rural areas, which generate 45-50% of its total sales.
High healthcare base a challenge but a diversified portfolio will aid growth
Further rise in competitive intensity in categories like shampoo, oral care, hair oils, juice (ITC has come out with aggressive ads and national rollout) may put pressure on volumes.
Dolat Capital
Maintains ‘reduce', cuts target price to Rs 562 from Rs 578, still implying a potential upside of 6%.
Consumption slowdown was more than anticipated.
Revises its FY23/24E EPS estimates at Rs 11.2/12.5 to factor in slowdown in rural markets and downtrading in urban areas.
However, it has maintained margin estimates at 20.3% to factor in price pass on and operating efficiencies.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.